Cboe BZX · PTNTHealthcarePharmaceuticals

Corgi IP Licensing & Royalties ETF financials

$24.11−1.84%
Close Sep 28, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY26
Jun 30
Revenue$13.2M
Gross profit$13.2M
Gross margin100.0%
Operating income-$8.7M
Net income-$8.4M
Net margin−63.5%
Diluted EPS$-2.96
EBITDA-$8.6M
Operating cash flow-$13.5M
Free cash flow-$13.6M
Diluted shares2.8M

Balance sheet

Period endJun 30
Cash & equivalents$7.5M
Short-term investments$0.00
Total debt$0.00
Total assets$8.5M
Total liabilities$1.8M
Shareholders' equity$6.7M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology